Showing posts with label World Health Organization. Show all posts
Showing posts with label World Health Organization. Show all posts

Sunday, July 14, 2019

Sri Lanka is measles-free: Will India achieve its target of eliminating measles by 2020?




Last week, Sri Lanka was declared free of measles by the World Health Organization (WHO). The country reported its last case of measles caused by an indigenous virus in May 2016. Sporadic cases, reported in the last three years have all been importations that were quickly detected, investigated and rapidly responded to, said the WHO.

Measles is a notifiable disease in Sri Lanka, which has a strong surveillance system in place and all vaccine-preventable diseases are an integral part of the communicable disease surveillance system. 

In contrast, there has been a resurgence of measles in the United States. This year 1,109 individual cases of measles have been confirmed in the US from January 1 to July 3, as per CDC. This is the greatest number of cases reported in the US since 1992 and since measles was declared eliminated in 2000. Two factors have been identified as contributing to the outbreaks of measles; firstly, measles is being imported into the US via travelers with measles who bring the disease from other countries such as Israel, Ukraine, and the Philippines, where large measles outbreaks (defined as 3 or more cases) are occurring and secondly, the low vaccination rates because of vaccine refusal facilitates spread in unvaccinated people.

Europe too has witnessed a resurgence of measles, with Ukraine experiencing the worst outbreak in the region, totaling more than 25,000 cases recorded in the first two months of 2019.

Measles is a highly infectious disease that is potentially fatal. It spreads via airborne transmission through sneezing or coughing. 

Measles is still common in many parts of the world including in India.

India has set itself a target of eliminating measles from the country by 2020. Towards this end, the Health Ministry launched a single “Measles-Rubella vaccine” for dual protection against the two diseases as part of Universal Immunization Program (UIP) in 2017. A total of 13.04 crore children have been vaccinated till 29th October 2018. Following the campaign, Measles-Rubella vaccine will be introduced in routine immunization, replacing the currently given two doses of measles vaccine, at 9-12 months and 16-24 months of age. 

What India can do?

India accounts for one-third of all measles-related deaths worldwide. To achieve its target of eliminating measles from India, the first step should be to strengthen the surveillance system.

At least 95% of population must have immunity to spread of measles i.e. not less than 95% of the population must be vaccinated against measles to ensure community protection for everyone “herd immunity”. This happens when unvaccinated people are protected because so many of those around them are. About 15% of vaccinated children fail to develop immunity from the first dose, meaning that if only 80% are fully immunized, an outbreak is likely.

This calls for intensification of efforts to ensure maximum coverage of the population with the MR vaccine.

Dr KK Aggarwal
Padma Shri Awardee
President Elect Confederation of Medical Associations in Asia and Oceania   (CMAAO)
Group Editor-in-Chief IJCP Publications
President Heart Care Foundation of India
Past National President IMA

Sunday, June 2, 2019

Transgender is not a mental disorder



 (Excerpts from CNN News)

The World Health Organization (WHO) uses the term “gender incongruence” to describe people whose gender identity is different from the gender they were assigned at birth.

Now, the WHO is moving this term to the panel's sexual health chapter from its mental disorders chapter. The new classification will improve social acceptance among transgender people while still making important health resources available.

The new standard of classification appears in the 11th revision of the International Statistical Classification of Diseases and Related Health Problems (ICD-11), which was adopted Saturday by the World Health Assembly in Geneva, Switzerland. It will go into effect on January 1, 2022.

The WHO does not expect the ICD change to affect transgender people's need for health care.

This is not the first time the ICD has changed a classification related to sexuality. In 1990, the WHO declared that "sexual orientation alone is not to be regarded as a disorder."

Dr KK Aggarwal
Padma Shri Awardee
President Elect Confederation of Medical Associations in Asia and Oceania   (CMAAO)
Group Editor-in-Chief IJCP Publications
President Heart Care Foundation of India
Past National President IMA

Wednesday, May 8, 2019

Biosimilars in India


Biosimilar is a biologic product, which is very similar to the reference product that has been FDA approved and does not differ much from the reference product with regard to safety and effectiveness.1 Only the indications and conditions of use that have been approved for the reference drug can be approved for the biosimilar

Biosimilars have been defined in various ways by regulating bodies around the world. Let’s take a look at some definitions:

· World Health Organization (WHO): A similar biotherapeutic product (SBP) is a “biotherapeutic product which is similar in terms of quality, safety and efficacy to an already licensed reference biotherapeutic product”. 2

·  US FDA: “A biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from an existing FDA-approved reference product”. 3 

o    In this definition, “no clinically meaningful differences” means that a manufacturer must also demonstrate that its proposed biosimilar product has no clinically meaningful differences from the reference product in terms of safety, purity, and potency (safety and effectiveness). 
o    “Highly similar” means that a manufacturer developing a proposed biosimilar demonstrates that its product is highly similar to the reference product by extensively analyzing (i.e., characterizing) the structure and function of both the reference product and the proposed biosimilar.

·  European Union: A biosimilar is a biological medicine highly similar to another biological medicine already approved in the EU (the so-called ‘reference medicine’). 4

· Health Canada: Biosimilar biologic drug is “a biologic drug that obtains market authorization subsequent to a version previously authorized in Canada and with demonstrable similarity to a reference biologic drug.” Biosimilars were previously referred to as Subsequent Entry Biologics (SEBs) in Canada. 5

· CDSCO: “A Similar Biologic product is a biological product/ drug produced by genetic engineering techniques and claimed to be “similar” in terms of safety, efficacy and quality to a reference biologic, which has been granted a marketing authorization in India by DCGI on the basis of a complete dossier, and with a history of safe use in India.” 6

Omnitrope, a somatropin biosimilar was the first biosimilar in Europe to be approved by the European Medicines Agency (EMA) in 2006. 7 However, the US FDA approval for the first biosimilar in the country came in 2015, when it approved the first biosimilar to filgrastim, a granulocyte colony-stimulating factor. 1

The first biosimilar in India was approved in 2000 for hepatitis B. Recently, Herceptin (active drug trastuzumab) became the first biosimilar manufactured in India to be FDA approved for certain breast and stomach cancer. 1

Biosimilars in India are listed in the Table below. 8

Biosimilar
Product Description
Adfrar
biosimilar adalimumab for the treatment of auto immune disorders
Toritz RA
Biosimilar rituximab
Reditux
Biosimilar rituximab (mAb targeting CD20)
Grafeel
Filgrastim (recombinant granulocyte-macrophage colony-stimulating factor, G-CSF)
Cresp
Darbepoetin alfa (recombinant erythropoietin)
Peg-grafeel
(pelfilgrastim)
Actorise
darbepoetin alfa in collaboration with Cipla
Neukine
Filgrastim (recombinant G-CSF)
Neupeg
PEGylated G-CSF
Intalfa
Recombinant human interferon alpha-2b
Epofit
Recombinant erythropoietin
Mbtas
Rituximab
Shanferon
Recombinant interferon alpha-2b
Shankinase
Recombinant streptokinase
Shanpoietin
Recombinant erythropoietin
ReliPoietin
Recombinant erythropoietin
ReliGrast
Recombinant G-CSF
ReliFeron
Recombinant interferon alpha-2b
Relibeta
Interferon beta-la
MIRel
Recombinant reteplase (tissue plasminogen activator)
Wepox
Recombinant erythropoietin
Wosulin
Recombinant insulin
Eripro
Recombinant human erythropoietin
Biomab
Biosimilar nimotuzumab (humanized mAb targeting epidermal growth factor receptor)
Nufil
Filgrastim, recombinant G-CSF
Myokinase
Recombinant streptokinase biosimilar
Insugen
Recombinant human insulin
Alzumab
Itolizumab
Basalog
Insulin glargine

References

1.     Meher BR, et al. Biosimilars in India; current status and future perspectives. J Pharm Bioallied Sci. 2019;11(1):12-15.

2.     Guidelines on evaluation of similar biotherapeutic products (SBPs), WHO 2009.

3.     Biological product definitions, US FDA 2017.

4.     Biosimilars in the EU. European Medicines Agency and the European Commission, 2017.

5.     Information and Submission Requirements for Biosimilar Biologic Drugs, Health Canada, 2016.

6.     Guidelines on similar biologic: Regulatory requirements for marketing authorization in India, 2012.

7.     Iughetti L, et al. Long-term safety and efficacy of Omnitrope®, a somatropin biosimilar, in children requiringgrowth hormone treatment: Italian interim analysis of the PATRO Children study. Ital J Pediatr. 2016;42(1):93.

8.     Rushvi P, et al. Biosimilars: an emerging market opportunities in India. Pharmaceut Reg Affairs.2016;5:165. 


Dr KK Aggarwal
Padma Shri Awardee
President Elect Confederation of Medical Associations in Asia and Oceania   (CMAAO)
Group Editor-in-Chief IJCP Publications
President Heart Care Foundation of India
Past National President IMA

Friday, April 19, 2019

Digital health technology as an aid towards universal health coverage


The World Health Organization (WHO) has released its first guideline on the use of digital health interventions via mobile phones, tablets and computers.

The guideline has also defined some of the terms in common use today such as digital health, eHealth, mHealth.

eHealth is “the use of information and communications technology in support of health and health-related fields”. 

mHealth or mobile health is “the use of mobile wireless technologies for health”. It is a subset of eHealth.

Digital health is “the use of digital technologies for health” and is “a broad umbrella term encompassing eHealth (which includes mHealth), as well as emerging areas, such as the use of advanced computing sciences in ‘big data’, genomics and artificial intelligence”.

WHO has identified 10 ways by which digital technology can be harnessed to improve people’s health and essential services. The key recommendations include:

1.     Birth notification via mobile devices: To be used in settings where the notifications provide individual-level data to the health system and/or a civil registration and vital statistics (CRVS) system, and the health system and/or CRVS system has the capacity to respond to the notifications.

2.     Death notification via mobile devices: To be used in the context of rigorous research, in settings where the notifications provide individual-level data to the health system and/or a CRVS system, and the health system and/or CRVS system has the capacity to respond to the notifications.

3.     Stock notification and commodity management via mobile devices: To be used in settings where supply chain management systems have the capacity to respond in a timely and appropriate manner to the stock notifications.

4.     Client-to-provider telemedicine: To be used to complement, rather than replace, the delivery of health services and in settings where patient safety, privacy, traceability, accountability and security can be monitored.

5.     Provider-to-provider telemedicine: To be used in settings where patient safety, privacy, traceability, accountability and security can be monitored

6.     Targeted client communication via mobile devices: To be used for health issues regarding sexual, reproductive, maternal, newborn, and child health under the condition that potential concerns about sensitive content and data privacy can be addressed

7.     Health worker decision support via mobile devices: To be used for community and facility-based health workers in the context of tasks that are already defined within the scope of practice for the health worker.

8.     Digital tracking of clients’ health status and services combined with decision support: To be used in settings where the health system can support the implementation of these intervention components in an integrated manner; and for tasks that are already defined as within the scope of practice for the health worker.

9.     Digital tracking combined with (a) health care worker decision support and (b) targeted client communication: To be used where the health system can support the implementation of these intervention components in an integrated manner, for tasks that are already defined as within the scope of practice for the health worker; and where potential concerns about data privacy and transmitting sensitive content to clients can be addressed.

10.  Digital provision of training and educational content to health workers via mobile devices/mobile learning (mLearning): To be used to complement, rather than replace, traditional methods of delivering continued health education and post-certification training.

Dr KK Aggarwal
Padma Shri Awardee
President Elect Confederation of Medical Associations in Asia and Oceania   (CMAAO)
Group Editor-in-Chief IJCP Publications
President Heart Care Foundation of India
Past National President IMA